196 related articles for article (PubMed ID: 34007618)
1. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
Langley PC
Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
[TBL] [Abstract][Full Text] [Related]
2. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
[TBL] [Abstract][Full Text] [Related]
3. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
[TBL] [Abstract][Full Text] [Related]
4. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
[TBL] [Abstract][Full Text] [Related]
5. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
[TBL] [Abstract][Full Text] [Related]
6. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
Langley PC
Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
[TBL] [Abstract][Full Text] [Related]
7. More Unnecessary Imaginary Worlds - Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review's Draft Evidence Report.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017638
[TBL] [Abstract][Full Text] [Related]
8. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
Langley PC
Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
[TBL] [Abstract][Full Text] [Related]
9. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
[TBL] [Abstract][Full Text] [Related]
10. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
[TBL] [Abstract][Full Text] [Related]
11. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
[TBL] [Abstract][Full Text] [Related]
12. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
[TBL] [Abstract][Full Text] [Related]
13. Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement.
Langley PC
Innov Pharm; 2020; 11(2):. PubMed ID: 34007612
[TBL] [Abstract][Full Text] [Related]
14. More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017637
[TBL] [Abstract][Full Text] [Related]
15. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
[TBL] [Abstract][Full Text] [Related]
16. The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment.
Langley PC
Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32668706
[TBL] [Abstract][Full Text] [Related]
17. Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22.
Langley P
F1000Res; 2022; 11():248. PubMed ID: 35444797
[TBL] [Abstract][Full Text] [Related]
18. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
[No Abstract] [Full Text] [Related]
19. Measurement, modeling and QALYs.
Langley PC; McKenna SP
F1000Res; 2020; 9():1048. PubMed ID: 33093950
[TBL] [Abstract][Full Text] [Related]
20. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
Langley PC
Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
